- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01903109
Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions
January 19, 2018 updated by: Roxane Laboratories
A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Cevimeline 30 mg under fed conditions
Study Overview
Study Type
Interventional
Enrollment (Actual)
27
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Nevada
-
Las Vegas, Nevada, United States, 89121
- Novum Pharmaceutical Research Services
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening
Exclusion Criteria:
- Positive test for HIV, Hepatitis B, or Hepatitis C.
- Treatment with known enzyme altering drugs.
- History of allergic or adverse response to cevimeline or any comparable or similar product.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Cevimeline first, the Evoxac
Single dose 30 mg cevimeline capsule, then single dose 30 mg Evoxac capsule (after washout period)
|
Other Names:
|
Active Comparator: First Evoxac, then cevimeline
Single dose 30 mg Evoxac capsule, then single dose 30 mg cevimeline capsule (after washout period)
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
bioequivalence determined by statistical comparison Cmax
Time Frame: 33 Days
|
33 Days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Darin Brimhall, DO, Novum Pharmaceutical Research Services
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2009
Primary Completion (Actual)
February 1, 2009
Study Completion (Actual)
February 1, 2009
Study Registration Dates
First Submitted
July 12, 2013
First Submitted That Met QC Criteria
July 16, 2013
First Posted (Estimate)
July 19, 2013
Study Record Updates
Last Update Posted (Actual)
January 23, 2018
Last Update Submitted That Met QC Criteria
January 19, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Stomatognathic Diseases
- Mouth Diseases
- Salivary Gland Diseases
- Xerostomia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Cholinergic Agonists
- Parasympathomimetics
- Muscarinic Agonists
- Cevimeline
Other Study ID Numbers
- CEVI-C30-PVFD-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Mouth
-
Maastricht University Medical CenterCompletedPatients of Advanced Age (≥ 70 Years) With a Clinical Diagnosis of Chronic Dry MouthNetherlands
-
Dow University of Health SciencesCompleted
-
Riyadh Colleges of Dentistry and PharmacyUnknownDry SocketSaudi Arabia
-
National University of MalaysiaCompletedXerostomia | Dry MouthMalaysia
-
Procter and GambleCompleted
-
Roxane LaboratoriesCompletedDry MouthUnited States
-
Roxane LaboratoriesCompleted
-
British University In EgyptCompletedSalivary Gland Diseases | Dry MouthEgypt
-
SunBio, Inc.NAMSA; RudacureCompleted
Clinical Trials on Cevimeline
-
Daiichi Sankyo, Inc.CompletedHead and Neck Cancer | Radiation Toxicity | Oral ComplicationsUnited States
-
Roxane LaboratoriesCompletedDry MouthUnited States
-
American Academy of Otolaryngology-Head and Neck...Duke UniversityCompleted
-
University of KentuckyCompleted